ARS Pharmaceuticals, Inc. Variable Lease, Cost
ARS Pharmaceuticals, Inc. (SPRY) reported Variable Lease, Cost of $119.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2022-11-02
- ARS Pharmaceuticals, Inc. variable lease, cost for the quarter ending 2022-09-30 was $119.00K, a 1.65% decline year-over-year.
- ARS Pharmaceuticals, Inc. variable lease, cost for the quarter ending 2022-06-30 was $119.00K, a 12.26% increase year-over-year.
- ARS Pharmaceuticals, Inc. variable lease, cost for the quarter ending 2022-03-31 was $135.00K, a 27.36% increase year-over-year.
- ARS Pharmaceuticals, Inc. variable lease, cost for the quarter ending 2021-12-31 was $126.00K, a 44.83% increase year-over-year.
- ARS Pharmaceuticals, Inc. variable lease, cost for fiscal 2021 was $459.00K, a 18.91% increase from fiscal 2020.
- ARS Pharmaceuticals, Inc. variable lease, cost for fiscal 2020 was $386.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2022-09-30 | $119.00K 10-Q · filed 2022-11-02 | $238.00K derived: sum of 2 quarters · filed 2022-11-02 | $373.00K 10-Q · filed 2022-11-02 | $499.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | $119.00K 10-Q · filed 2022-08-11 | $254.00K 10-Q · filed 2022-08-11 | $380.00K derived: sum of 3 quarters · filed 2022-08-11 | $501.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-03-31 | $135.00K 10-Q · filed 2022-05-12 | $261.00K derived: sum of 2 quarters · filed 2022-05-12 | $382.00K derived: sum of 3 quarters · filed 2022-11-02 | $488.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $247.00K derived: sum of 2 quarters · filed 2022-11-02 | $353.00K derived: sum of 3 quarters · filed 2022-11-02 | $459.00K 10-K · filed 2022-03-31 |
| 2021-09-30 | $121.00K 10-Q · filed 2022-11-02 | $227.00K derived: sum of 2 quarters · filed 2022-11-02 | $333.00K 10-Q · filed 2022-11-02 | $420.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $106.00K 10-Q · filed 2022-08-11 | $212.00K 10-Q · filed 2022-08-11 | $299.00K derived: sum of 3 quarters · filed 2022-08-11 | $418.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $106.00K 10-Q · filed 2022-05-12 | $193.00K derived: sum of 2 quarters · filed 2022-05-12 | $312.00K derived: sum of 3 quarters · filed 2022-05-12 | $406.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $206.00K derived: sum of 2 quarters · filed 2022-03-31 | $300.00K derived: sum of 3 quarters · filed 2022-03-31 | $386.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $119.00K 10-Q · filed 2021-11-10 | $213.00K derived: sum of 2 quarters · filed 2021-11-10 | $299.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $94.00K 10-Q · filed 2021-08-12 | $180.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $86.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |